Clinical Trials
60 trialsREAL-LU
Novartis
TNE-bien-DIF
Assistance Publique - Hôpitaux de Paris
LUTATHERA Injection General Use Result Survey
Novartis
EchoTip AcuCore Post-Market Clinical Study
Cook Group Incorporated
GAPET-NET
University Hospital, Brest
GEP-NENs
Tongji Hospital
NUTRIGETNE
Grupo Espanol de Tumores Neuroendocrinos
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases
First Affiliated Hospital, Sun Yat-Sen University
TEGRELE
Central Hospital, Nancy, France
NEMESIs
University Hospital, Basel, Switzerland
AIM-NETs
Asan Medical Center
ECHO-NET
Istituto Clinico Humanitas
BackSOM
Ipsen
ROOT
Taproot Health
PREF-NET
Ipsen
SurvivApp
Insel Gruppe AG, University Hospital Bern
RELAX
TerSera Therapeutics LLC
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Pfizer
BANN
University Medical Center Groningen
VIDEO-NET
University Medical Center Groningen
5-HIAA
University Medical Center Groningen
HET-NET
University Medical Center Groningen
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
University Medical Center Groningen
JPETClinic
Jagiellonian University
Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors
Sun Yat-sen University
ReSiPaTNE
University Hospital, Strasbourg, France
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
SELFIE
King's College London
NutriGIT
University Medicine Greifswald
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Memorial Sloan Kettering Cancer Center
A Real-world Comparison of FNB and FNA in IHC-required Lesions.
Huazhong University of Science and Technology
Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan
National Health Research Institutes, Taiwan
HRQoL During PRRT in Patients With NETs
Uppsala University
NET-SEQ
University Health Network, Toronto
EXPLAIN
Ipsen
RESiN
Vanderbilt-Ingram Cancer Center
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
PET/Ga68
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis
IRCCS Azienda Ospedaliero-Universitaria di Bologna
TNE-P-Ki
Institut Paoli-Calmettes
18F-AmBF3-TATE PET/CT for Imaging NET Patients
British Columbia Cancer Agency
SYMNET
Ipsen
OPERA
Ipsen
Community-based Neuroendocrine Tumor (NET) Research Study
Ipsen
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
Ipsen
The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET
Vastra Gotaland Region
CRIPNET
Grupo Espanol de Tumores Neuroendocrinos
NETMRI
CHU de Reims
PanTEN
University Hospital, Montpellier